# Research, Outcomes & Benchmarking Blueprint

Status: GOVERNING FUTURE DOMAIN BLUEPRINT
Phase: P3/P5

## Purpose

Create a lawful, evidence-based layer for proving product value, supporting institutional research, validating operational/clinical outcomes where appropriate and eventually providing de-identified benchmarking without turning patient data sale into the business model.

## Personas

- product leadership
- clinical leadership
- enterprise customer
- payer/value-based organization
- researcher/institution
- customer success
- investor diligence

## Frontend surfaces

- customer value evidence
- before/after operational outcomes
- measure definitions
- research project registry
- approved study datasets/workspaces
- de-identified benchmark reports
- methodology/provenance detail

## Domain authority

Research/Outcomes owns study definitions, evidence aggregation and approved derived outcome/benchmark products. Source clinical/financial/operational facts remain owned by their original domains.

## Backend services

- OutcomeDefinitionService
- StudyRegistryService
- EvidenceCohortService
- ResearchAuthorizationService
- DeidentificationPolicyService
- BenchmarkingService
- MethodologyVersionService
- OutcomeEvidenceService

## Canonical data

OutcomeDefinition, Study, CohortDefinition, ResearchAuthorization, EvidenceSnapshot, MethodologyVersion, BenchmarkMetric, BenchmarkCohort, PublicationReference.

## Outcome categories

- implementation time
- time to first value
- provider documentation burden
- appointment readiness
- referral closure
- unresolved work age
- coding/claim exception rate
- denial/reconciliation workflow
- customer software cost
- capacity utilization
- workforce fill rate
- EDU completion/workforce outcomes
- quality/outcome measures only when validated and appropriate

## Evidence labels

Every claim must state whether it is:

- potential
- estimated
- internally observed
- customer verified
- independently validated
- published/peer-reviewed

## Research governance

If a project constitutes regulated human-subject research or otherwise requires institutional/ethical review, do not treat product analytics consent as research authorization. Support separate review/consent/data-use workflows as applicable.

## De-identified benchmarking

Only after strong governance. Require:

- defensible de-identification methodology
- cohort minimums/suppression rules
- contractual/data-use rights
- re-identification risk review
- no patient-level resale
- versioned metric definitions

## Zumi

May summarize approved aggregate findings and methodology. It must not fabricate causal claims or present correlation as proven clinical outcome.

## Economics

Supports customer proof, payer/enterprise sales, institutional research partnerships and future benchmarking/intelligence products where lawful.

## Tests

- source provenance
- methodology versioning
- cohort privacy/suppression
- authorization
- claim-label enforcement
- tenant/customer data separation

## Definition of done

Every externally used outcome/benchmark claim can be traced to a versioned methodology, approved data use and evidence level, with privacy safeguards and no unsupported causal language.